Terug
62
19
Ook genoteerd als
SKHHY
OTC
Dagbereik
€ 15,00
€ 15,00
52-Weeksbereik
€ 12,70
€ 19,34
Volume
180
50D / 200D Gem.
€ 14,99
/
€ 15,85
Vorige Slotkoers
€ 15,00
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 14,4 | 0,3 |
| P/B | 0,9 | 2,9 |
| ROE % | 6,3 | 3,7 |
| Net Margin % | 5,3 | 3,8 |
| Rev Growth 5Y % | 2,5 | 10,0 |
| D/E | 0,6 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2029 |
€ 1,69
€ 1,64 – € 1,74
|
13 B | 1 |
| FY2028 |
€ 1,57
€ 1,53 – € 1,62
|
13 B | 1 |
| FY2027 |
€ 1,45
€ 1,40 – € 1,49
|
12 B | 1 |
Belangrijkste Punten
Revenue grew 2,45% annually over 5 years — modest growth
Generating 960,55M in free cash flow
P/E of 14,43 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 5,51%
Cash machine — converts 187,02% of earnings into free cash flow
Capital efficient — spends only 3,49% of revenue on capex
Groei
Revenue Growth (5Y)
2,45%
Revenue (1Y)7,96%
Earnings (1Y)0,49%
FCF Growth (3Y)-0,69%
Kwaliteit
Return on Equity
6,32%
ROIC16,23%
Net Margin5,32%
Op. Margin30,28%
Veiligheid
Debt / Equity
0,62
Current Ratio1,17
Interest Coverage16,18
Waardering
P/E Ratio
14,43
P/B Ratio0,89
EV/EBITDA4,08
Dividend Yield0,04%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7,96% | Revenue Growth (3Y) | 8,82% |
| Earnings Growth (1Y) | 0,49% | Earnings Growth (3Y) | -13,41% |
| Revenue Growth (5Y) | 2,45% | Earnings Growth (5Y) | -20,95% |
| Profitability | |||
| Revenue (TTM) | 9,65B | Net Income (TTM) | 513,60M |
| ROE | 6,32% | ROA | 3,20% |
| Gross Margin | 33,05% | Operating Margin | 30,28% |
| Net Margin | 5,32% | Free Cash Flow (TTM) | 960,55M |
| ROIC | 16,23% | FCF Growth (3Y) | -0,69% |
| Safety | |||
| Debt / Equity | 0,62 | Current Ratio | 1,17 |
| Interest Coverage | 16,18 | Dividend Yield | 0,04% |
| Valuation | |||
| P/E Ratio | 14,43 | P/B Ratio | 0,89 |
| P/S Ratio | 0,77 | PEG Ratio | 0,00 |
| EV/EBITDA | 4,08 | Dividend Yield | 0,04% |
| Market Cap | 7,41B | Enterprise Value | 11,91B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 9,65B | 8,93B | 8,14B | 9,34B | 8,75B |
| Net Income | 513,60M | 511,09M | 684,98M | 1,46B | 1,32B |
| EPS (Diluted) | 1,07 | 1,07 | 1,45 | 3,02 | 2,73 |
| Gross Profit | 3,19B | 7,48B | 6,87B | 7,74B | 3,43B |
| Operating Income | 2,92B | 2,69B | 2,63B | 3,52B | 3,18B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 16,05B | 14,83B | 13,56B | 12,55B | 11,76B |
| Total Liabilities | 7,58B | 6,75B | 5,64B | 5,12B | 5,26B |
| Shareholders' Equity | 8,32B | 7,92B | 7,74B | 7,27B | 6,38B |
| Total Debt | 5,17B | 4,52B | 3,10B | 3,01B | 3,23B |
| Cash & Equivalents | 673,77M | 645,00M | 797,99M | 780,00M | 899,83M |
| Current Assets | 2,61B | 2,35B | 2,13B | 2,31B | 2,28B |
| Current Liabilities | 2,22B | 2,32B | 1,88B | 2,08B | 2,22B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#199 of 1052
#467 of 618
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026